Hims & Hers Q2 Revenue Up 73% Y/Y, On Track for $2.4 Billion Annual Revenue

Hims & Hers reported Q2 revenue of $545 million, up 73% YoY, putting them on track for $2.4 billion in annual revenue. The company is considered undervalued in the telehealth space, with a growth story that could potentially yield 4.2% monthly returns.

Hims & Hers Health, Inc. (HIMS) has reported its Q2 revenue for 2025, showing a significant increase of 73% year-over-year (YoY), reaching $545 million. This performance positions the company on track to achieve annual revenue of $2.4 billion. The growth is attributed to the company's expansion into new therapeutic categories, vertical integration, and international market penetration.

The company's weight loss specialty, anchored in GLP-1 treatments, continues to drive subscriber retention rates above industry averages. This is supported by continuous provider engagement and integrated digital support. Additionally, Hims & Hers is preparing to expand its offerings into hormonal health, targeting menopause and low testosterone conditions, which represent substantial market opportunities in the U.S.

International expansion remains a key growth driver. The acquisition of ZAVA has extended Hims & Hers' footprint across the U.K., Germany, France, and Ireland, providing immediate access to over 1.3 million existing patients. Planned entry into Canada in 2026, aligned with the introduction of generic semaglutide, will make weight loss treatments more affordable and accessible, especially in regions with high obesity rates.

Hims & Hers is also expected to grow its earnings and revenue by 13.9% and 14.7% per annum respectively, with EPS growth forecasted at 15.6% per annum. The company's forward 12-month price-to-sales (P/S) ratio stands at 3.8X, which is lower than the industry average of 5.8X but higher than its three-year median of 2.4X. Despite the strong financial performance, the stock is considered undervalued, with potential for 4.2% monthly returns [1].

The company's stock has gained 86.5% year-to-date, outperforming the industry's growth of 23.5%. The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 137% improvement from 2024. However, the stock carries a Zacks Rank #3 (Hold), indicating a cautious outlook from analysts [1].

Hims & Hers' growth strategy includes a focus on personalized healthcare, leveraging digital platforms to deliver integrated care solutions. The company's transformation into a precision health platform is expected to enhance patient lifetime value and position it as a leader in long-term health optimization and proactive care.

References:
[1] https://www.nasdaq.com/articles/hims-hers-fuels-growth-market-expansion-and-new-care-verticals
[2] https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/future